+

USRE47589E1 - Phosphoramidate compounds and methods of use - Google Patents

Phosphoramidate compounds and methods of use Download PDF

Info

Publication number
USRE47589E1
USRE47589E1 US15/279,611 US200415279611A USRE47589E US RE47589 E1 USRE47589 E1 US RE47589E1 US 200415279611 A US200415279611 A US 200415279611A US RE47589 E USRE47589 E US RE47589E
Authority
US
United States
Prior art keywords
nmr
mhz
mmol
cdcl
oph
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US15/279,611
Other languages
English (en)
Inventor
Christopher McGuigan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nucana PLC
Original Assignee
Nucana PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27772362&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE47589(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nucana PLC filed Critical Nucana PLC
Priority to US15/279,611 priority Critical patent/USRE47589E1/en
Assigned to NuCana plc reassignment NuCana plc CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: NUCANA BIOMED LIMITED
Application granted granted Critical
Publication of USRE47589E1 publication Critical patent/USRE47589E1/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to nucleotide derivatives and their use in the treatment of cancer.
  • Nucleoside analogues such as fluorodeoxyuridine (1), cytarabine (2) and gemcitabine (3) are well established as anticancer agents. They function as inhibitors of DNA synthesis after activation to their 5′-phosphate form.
  • the phosphate prodrugs have biological properties and therapeutic activities that are similar to, or somewhat lower than, the parent nucleoside analogue.
  • Lackey et al [Biochem Pharmacol., 2001, 61, 179-89] have reported the application of our phosphoramidate pro-drug method for antiviral nucleosides to the anti-herpetic agent bromovinyl-2′-deoxyuridine (BVDU) (6).
  • BVDU bromovinyl-2′-deoxyuridine
  • phenyl methoxyalaninyl phosphoramidate (7) has significant anti-cancer activity. This is in marked contrast to the parent (antiviral) nucleoside (6).
  • a pharmaceutically acceptable derivative is meant any pharmaceutically acceptable salt, ester or salt of such ester or any other compound which upon administration to a recipient is capable of providing (directly or indirectly) a compound of formula (I).
  • R is 2-Bu (—CH 2 —CH(CH 3 ) 2 ) and one of R′ and R′′ is H and one of R′ and R′′ is methyl (—CH 3 ), when n is 1 and X and Y are both H, then Ar is not unsubstituted phenyl (—C 6 H 5 ).
  • metabolite is meant a metabolite or residue of a
  • n, Q, R, R′, R′′, X, Y, Z and Z′ have the meanings described above and below for formula I, and additionally R can be H, with the proviso that when n is 1, X and Y are both H, R is methyl (—CH 3 ), one of R′ and R′′ is H and one of R′ and R′′ is methyl (—CH 3 ), then Z is not —CH ⁇ CHBr.
  • ROCOCR′R′′NH— corresponds neither to alanine (ie as above, R is not methyl (—CH 3 ), one of R′ and R′′ is not H and one of R′ and R′′ is not methyl (—CH 3 )) nor to tryptophan (ie ⁇ -amino- ⁇ -indolylpropionic acid).
  • ROCOR′R′′NH is neither derived from nor corresponds to any naturally occurring amino acid.
  • the moiety ROCOCR′R′′NH— does not correspond to alanine (ie R is not methyl (—CH 3 ), one of R′ and R′′ is is not H and one of R′ and R′′ is not methyl (—CH 3 )), does not preferably correspond to tryptophan, and even more preferably the said moiety does not correspond to any naturally occurring amino acid.
  • ROCOCR′R′′NH— in compounds of formula II corresponds to a non-naturally occurring amino acid.
  • an alkyl group means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical.
  • the alkylene group is preferably C 3 to C 12 , more preferably C 5 to C 10 , more preferably C 5 to C 7 .
  • the alkyl group is preferably C 1 to C 16 , more preferably C 1 to C 6 .
  • an aryl group means an aromatic group containing 5 to 14 ring atoms, for example phenyl or naphthyl.
  • the aromatic group may be a heteroaromatic group containing one, two, three or four, preferably one, heteroatoms selected, independently, from the group consisting of O, N and S.
  • heteroaromatic groups include pyridyl, pyrrolyl, furanyl and thiophenyl.
  • the aryl group comprises phenyl or substituted phenyl.
  • alkyl and aryl groups may be substituted or unsubstituted. Where substituted, there will generally be one to three substituents present, preferably one substituent.
  • Substituents may include halogen atoms, by which is meant F, Cl, Br and I atoms, and halomethyl groups such as CF 3 and CCl 3 ; oxygen containing groups such as oxo, hydroxy, carboxy, carboxyC 1-16 alkyl, alkoxy, alkoyl, alkoyloxy, aryloxy, aryloyl and aryloyloxy; nitrogen containing groups such as amino, C 1-6 alkylamino, diC 1-6 alkylamino, cyano, azide and nitro; sulphur containing groups such as thiol, C 1-6 alkylthiol, sulphonyl and sulphoxide; heterocyclic groups which may themselves be substituted; alkyl groups as defined above, which may themselves be substituted
  • alkoxy and aryloxy groups means, respectively, alkyl-O— (for example where alkyl is C 1 to C 16 , preferably C 1 to C 6 ) and aryl-O— (for example where aryl is a 5 to 14 membered aromatic mono- or bifused ring moiety, optionally containing 1, 2, 3 or 4 heteroatoms selected, independently, from O, S and N, preferably aryl is phenyl).
  • alkoyl and aryloyl groups means, respectively, alkyl-CO— (for example where alkyl is C 1 to C 16 , preferably C 1 to C 6 ) and aryl-CO— (for example where aryl is a 5 to 14 membered aromatic mono or bifused ring moiety, optionally containing 1, 2, 3 or 4 heteroatoms selected, independently, from O, S and N, preferably aryl is phenyl).
  • alkoyloxy and aryloyloxy means, respectively, alkyl-CO—O (for example where alkyl is C 1 to C 16 , preferably C 1 to C 6 ) and aryl-CO—O (for example where aryl is a 5 to 14 membered mono- or bifused aromatic ring system, optionally containing 1, 2, 3 or 4 heteroatoms selected, independently, from O, S and N, preferably aryl is phenyl).
  • heterocyclic groups means groups containing one or more, pyrrolyl, imidazolyl, pyraziolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranyl, pyronly, pyridyl, pyrazinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, thionaphthyl, benzofuranyl, isobenzofuryl, indolyl, oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-azaindolyl, isoindazolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolyl, is
  • the group Ar comprises a substituted or unsubstituted aryl group, wherein the term “aryl group” and the possible substitution of said group is as defined herein.
  • Ar is a substituted or unsubstituted phenyl group.
  • Particularly preferred substituents are electron withdrawing groups such as halogen (preferably chlorine or fluorine), trihalomethyl (preferably trifluoromethyl), cyano and nitro groups.
  • Ar can be phenyl, 3,5-dichloro-phenyl, p-trifluoromethyl-phenyl, p-cyano-phenyl, or p-nitro-phenyl.
  • Ar is a heteroaromatic group, preferably it is optionally substituted pyridyl.
  • R is a C 1-16 primary or secondary alkyl group, a C 5-7 carbocyclic aryl group or a C 1-6 alkylC 5-11 aryl group. More suitably, R is a C 1-10 alkyl group, a phenyl group or C 1-3 alkylC 5-7 aryl group. Preferably R is unsubstituted.
  • R is methyl (—CH 3 ), ethyl (—C 2 H 5 ), n- or i-propyl (—C 3 H 7 ), n- or i-butyl (—C 4 H 9 ) or benzyl (—CH 2 C 6 H 5 ).
  • R is benzyl.
  • R is preferably benzyl when one of R′ and R′′ is H and one of R′ and R′′ is methyl (—CH 3 ), especially when Ar is unsubstituted phenyl, n is 0 and each of X and Y is F.
  • R′ and R′′ are each independently selected from the group comprising H, C 1-6 primary, secondary or tertiary alkyl, C 1-3 alkylC 5-7 aryl, or, when together they form an alkylene chain, they provide, together the C atom to which they are attached, a C 3-8 carbocyclic aliphatic ring.
  • R′ and R′′ are the same and are alkyl, more preferably they are both methyl, ethyl or n- or i-propyl.
  • R′ and R′′ are, independently, H, methyl (—CH 3 ), secondary butyl (—CH 2 —CH—(CH 3 ) 2 ), benzyl (—CH 2 C 6 H 5 ), or, together with the C atom to which they are attached, provide a C 5-6 ring.
  • Preferred compounds include those where R′ and R′′ are both methyl, one of R′ and R′′ is H and one of R′ and R′′ is methyl, and R′ and R′′, together with the C atom to which they are attached, provide a pentyl ring.
  • the C atom to which they are attached is chiral.
  • the present compounds can be L or D or a mixture of stereoiosomers. Preferably they are L.
  • R′ and R′′ when one of R′ and R′′ is H and one of R′ and R′′ is Me or PhCH 2 , the moiety corresponds to alanine or phenylalanine, respectively.
  • the stereochemistry at the asymmetric centre —CR′R′′ corresponds to an L-amino acid.
  • the stereochemistry at the asymmetric centre —CR′R′′ can, however, correspond to a D-amino acid.
  • mixtures of of compounds can be employed having asymmetric centres corresponding to L and D amino acids.
  • naturally occurring amino acid we mean Alanine, Arginine, Asparagine, Aspartic Acid, Cysteine, Cystine, Glycine, Glutamic Acid, Glutamine, Histidine, Hydroxylysine, Hydroxyproline, Isoleucine, Leucine, Lysine, Methionine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine and Valine.
  • the present invention is not, however, limited to compounds having a moiety corresponding to a naturally occurring amino acid.
  • the moiety ROCOCR′R′′NH— corresponds to or is derived from a non-naturally occurring amino acid.
  • ROCOCR′R′′NH— preferably neither corresponds to nor is derived from alanine, more preferably neither corresponds to nor is derived from either of alanine or tryptophan, even more preferably neither corresponds to nor is derived from any naturally occurring amino acid.
  • ROCOCR′R′′NH— preferably neither corresponds to nor is derived from alanine, more preferably neither corresponds to nor is derived from either of alanine or trytophan, even more preferably neither corresponds to nor is derived from any naturally occurring amino acid.
  • Q is O.
  • X and Y are, independently, selected from the group comprising F, H and OH.
  • n 1, preferably each of X and Y is H.
  • each of X and Y is F, or X is OH and Y is H, or X is H and Y is OH.
  • n is 0 and X is OH and Y is H.
  • Particularly preferred are compounds of formula I wherein n is 0, X is OH, Y is H, Q is O and Z is H, corresponding to phosphoramidated cytarabine.
  • n is 0 and X is H and Y is OH.
  • Particularly preferred are compounds of formula I wherein n is 0, X is H, Y is OH, Q is O and Z is H, corresponding to phosphoramidated cytidine.
  • Ar is a 5 to 14 membered aromatic ring moiety.
  • the one or two rings may include 1, 2, 3 or 4 heteroatoms, preferably 1, selected, independently, from O, S and N.
  • Ar is a carbomonocyclic aromatic ring moiety. More preferably, Ar is a C 6 monocyclic aromatic ring moiety, ie is optionally substituted phenyl.
  • One, two, three or four substituents which may be the same or different, may be present on Ar and are selected from the group comprising halogen, which may —F, —Cl, —Br or —I; —NO 2 ; —NH 2 ; optionally substituted —C 1-3 alkyl; optionally substituted —C 1-3 alkoxy, preferably methoxy (—OCH 3 ); optionally substituted —SC 1-3 alkyl; —CN; optionally substituted —COC 1-3 alkyl; and optionally substituted —CO 2 C 1-3 alkyl.
  • halogen which may be —F, —Cl, —Br or —I
  • —NO 2 ; —NH 2 ; optionally substituted —C 1-3 alkyl; optionally substituted —C 1-3 alkoxy, preferably methoxy (—OCH 3 ); optionally substituted —SC 1-3 alkyl; —CN; optionally substituted —COC
  • the optional substitutents are one or more up to six, preferably three, members selected from the group comprising halogen which may be F, Cl, Br and I and NO 2 .
  • Preferred substituents on Ar include F, Cl, CF 3 , and NO 2 .
  • the substituents may be at any position on the ring moiety. Where the ring moiety is C 6 ie phenyl, a single substituent at the 2 (ortho) or 4 (para) position is preferred. Where Ar is phenyl, a single substituent at the 4 position is more preferred.
  • Ar is an optionally substituted phenyl moiety. More preferably, Ar is selected form the group comprising: Ph—, pCF 3 C 6 H 4 —, pFC 6 H 4 —, pNO 2 C 6 H 4 —, pClC 6 H 4 — and oClC 6 H 4 —.
  • Z is selected from the group comprising H, C 1-6 alkyl, substituted C 1-6 alkyl, C 1-6 alkenyl, substituted C 1-6 alkenyl, C 1-6 alkynyl, substituted C 1-6 alkynyl and halogen, where halogen is F, Cl, Br or I.
  • Substituents that may be present on the alkenyl or alkynyl moiety are selected from the group comprising F, Cl, Br, I, and —CO 2 Me. One, two or three substituents may be present.
  • the alkenyl and alkynyl groups may contain one or more sites of unsaturation.
  • Z is substituted alkenyl or alkynyl
  • the substituent is preferably on the terminal C atom.
  • Z is selected from the group comprising H, F, optionally substituted C 1-6 alkyl particularly Me (—CH 3 ), optionally substituted C 1-6 alkenyl and optionally substituted C 1-6 alkynyl, the optional substituents being as recited immediately above.
  • Z′ is O
  • Q is O
  • X and Y are each H
  • Z is a substituted C 2 alkenyl (i.e. ethenyl or vinyl) moiety (—CH ⁇ CH—); more preferably, Z is bromovinyl (—CH ⁇ CHBr) or methylpropenoate (—CH ⁇ CHCO 2 Me); and most preferably, Z is —CH ⁇ CHBr.
  • n 1 and X and Y are both H, then Z is not F.
  • X is not H and Y is not OH, more preferably X is OH and Y is H or X and Y are both F.
  • a preferred compound embodying the present invention is the benzyl ester (8). It has surprisingly been found that the benzyl ester (8) is very significantly more potent against several cancer cell lines than the methyl ester (7):
  • Compound (8) inhibits the growth of colon cancer cell line HT115 by 50% at 1.4 ⁇ M, whilst (7) requires a concentration of 244 ⁇ M; (8) is thus 174 times more potent. Compound (8) is also 8 times more potent than (7) versus prostate cancer cell line PC-3 (19 ⁇ M vs. 155 ⁇ M).
  • compound (11) has simultaneous modification in these two regions, being the p-trifluoromethylphenyl benzyl [ ⁇ , ⁇ -dimethylglycinyl ]phosphoramidate.
  • Compound 11 shows high potency against a range of cancer cell types and is significantly and surprisingly more potent than (7).
  • breast cancer (11) is 60-fold more active (1.3 ⁇ M vs 79 ⁇ M)
  • prostate cancer (11) is 254-fold more potent (0.61 ⁇ M vs. 155 ⁇ M).
  • colon cancer (11) is 35-fold more potent (7 ⁇ M vs 244 ⁇ M).
  • the degree of enhancement of the analogue (11) vs. (7) is surprising based on prior art.
  • comparing (12) [dimethyl glycine modification] and (13) [p-CF 3 phenyl modification] to (9) shows no significant difference in potency.
  • compounds embodying the present invention and having variations in one or more of the ester (R), amino acid (R′, R′′) and aryl (Ar) region of the phosphoramidate structure compared to phenyl methoxyalaninyl phosphoramidate can give surprising and substantial potency boosts of pro-tides derived from BVDU against a range of cancer cell types.
  • a compound having formula I according to the present invention for use in a method of treatment, preferably in the prophylaxis or treatment of cancer.
  • a method of phrophylaxis or treatment of cancer comprising administration to a patient in need of such treatment an effective dose of a compound having formula I according to the present invention.
  • a pharmaceutical composition comprising a compound having formula I of the present invention in combination with a pharmaceutically acceptable excipient, carrier or diluent.
  • a method of preparing a pharmaceutical composition comprising the step of combining a compound having formula I of the present invention with a pharmaceutically acceptable excipient, carrier or diluent.
  • the present invention is particularly applicable for the treatment of a patient having breast cancer, colon cancer or prostate cancer.
  • cancers include breast MDA MB231, colon HT115 and prostate PC-3.
  • the compound having formula I or pharmaceutical composition according to the present invention can be administered to a patient, which may be human or animal, by any suitable means.
  • the medicaments employed in the present invention can be administered by oral or parenteral routes, including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
  • oral or parenteral routes including intravenous, intramuscular, intraperitoneal, subcutaneous, transdermal, airway (aerosol), rectal, vaginal and topical (including buccal and sublingual) administration.
  • the compounds of the invention will generally be provided in the form of tablets or capsules, as a powder or granules, or as an aqueous solution or suspension.
  • Tablets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents and preservatives.
  • suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, and lactose, while cornstarch and alginic acid are suitable disintegrating agents.
  • Binding agents may include starch and gelatin, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc.
  • the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate, to delay absorption in the gastrointestinal tract.
  • Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.
  • Formulations for rectal administration may be presented as a suppository with a suitable base comprising for example cocoa butter or a salicylate.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations containing in addition to the active ingredient such carriers as are known in the art to be appropriate.
  • the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity.
  • Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
  • Aqueous suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin.
  • Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.
  • the compounds of the invention may also be presented as liposome formulations.
  • a suitable dose will be in the range of 0.1 to 300 mg per kilogram body weight of the recipient per day.
  • a preferred lower dose is 0.5 mg per kilogram body weight of recipient per day, a more preferred lower dose is 6 mg per kilogram body weight of recipient per day, an even more preferred lower dose is 10 mg per kilogram body weight per recipient per day.
  • a suitable dose is preferably in the range of 6 to 150 mg per kilogram body weight per day, and most preferably in the range of 15 to 100 mg per kilogram body weight per day.
  • the desired dose is preferably presented as two, three, four, five or six or more sub-doses administered at appropriate intervals throughout the day. These sub-doses may be administered in unit dosage forms, for example, containing 10 to 1500 mg, preferably 20 to 1000 mg, and most preferably 50 to 700 mg of active ingredient per unit dosage form.
  • TLC Thin layer chromatography
  • Phosphorus oxychloride (1.0 mol eq.) and the appropriate substituted phenol (1.0 mol) were stirred with anhydrous diethylether (31 mol eq.). To this was added anhydrous triethylamine (1.0 mol eq) at ⁇ 80° C. and left to rise to room temperature over 16 hrs the triethylamine hydrochloride salt was filtered off, and the filtrate reduced to dryness to give the crude product as a clear liquid.
  • the experimental procedures used human colon cancer cell line (HT115), human prostate cancer cell line (PC-3), human breast cancer cell line (MDA MB 231) and normal human umbilical vein endothelial cell (HUVEC). Compounds were diluted over a range of concentrations and added to cells over 1 to 3 days. The cytotoxity was determined using a MTT assay at the end of each experiment.
  • ArO refers to Ar as defined above with respect to formula I;
  • BVU stands for 2-bromovinyl uridine.
  • GemCyt stands for Gemcitabine.
  • Examples A, 1, 67 and G are comparative Examples.
  • Example A is 5-(2-Bromovinyl)-2′-deoxyuridine.
  • Example 1 is Example 1 above corresponding to compound (7) above.
  • Example 67 is propenate-2′-deoxyuridine.
  • Example G is gemcitabine.
  • Examples 51, 52 and 53 are compounds embodying formula II above.
  • Gemcitabine (Example G in the Table) and compound CPF31 (Example 31 in the Table: gemcitabine-[phenyl-(benzoxy-L-alaninyl)]-phosphate) were compared in a mouse model with xenografts of human cancer (colon HT115 and prostrate PC3).
  • mice were dosed daily at a range of concentrations (0.01-10 ⁇ M) and tumour volume assessed versus control.
  • FIG. 1 shows for the mouse xenograft the tumour volume for prostate data at day 13 using GemzarTM (gemcitabine available ex. Lilly);
  • FIG. 2 shows for the mouse xenograft the tumour volume for prostate data at day 13 using CPF31;
  • FIG. 3 shows the incident free survival functions v. day for each of CPF31 and gemcitabine.
  • FIG. 4 shows for the mouse xenograft the tumour volume for colon data at day 24 using, respectively, Gemzar and compound CPF31.
  • CPF31 can be seen to be significantly less toxic than gemcitabine.
  • CPF31 was significantly effective at reducing prostate and colon tumour volume relative to control at daily dosing of 5 and 10 ⁇ M (3 and 6 ⁇ g/ml). Gemcitabine was not effective at the highest non-toxic concentration.
  • Gemzar is seen from FIG. 1 to be toxic above 1 ⁇ M.
  • CPF31 is seen from FIG. 2 to have substantially lower toxicity.
  • FIG. 3 shows the Kaplan-Meier survival curve, incidence free survival: based on the loss according to weight loss.
  • FIG. 4 shows the results of testing both in vivo at 5 ⁇ M. The greater activity of CPF31 in reducing tumour volume is shown in FIG. 4 .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US15/279,611 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use Active 2026-07-25 USRE47589E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/279,611 USRE47589E1 (en) 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0317009.9 2003-07-21
GBGB0317009.9A GB0317009D0 (en) 2003-07-21 2003-07-21 Chemical compounds
US10/560,887 US7951787B2 (en) 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use
US15/279,611 USRE47589E1 (en) 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use
PCT/GB2004/003148 WO2005012327A2 (fr) 2003-07-21 2004-07-20 Composes chimiques

Publications (1)

Publication Number Publication Date
USRE47589E1 true USRE47589E1 (en) 2019-09-03

Family

ID=27772362

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/279,611 Active 2026-07-25 USRE47589E1 (en) 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use
US10/560,887 Ceased US7951787B2 (en) 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
US10/560,887 Ceased US7951787B2 (en) 2003-07-21 2004-07-20 Phosphoramidate compounds and methods of use

Country Status (20)

Country Link
US (2) USRE47589E1 (fr)
EP (5) EP3486251A1 (fr)
JP (1) JP4923216B2 (fr)
AU (1) AU2004261455B2 (fr)
CA (1) CA2518115C (fr)
CY (5) CY1117960T1 (fr)
DK (4) DK3040340T3 (fr)
ES (4) ES2708570T3 (fr)
FI (1) FIC20230013I1 (fr)
FR (1) FR23C1014I2 (fr)
GB (1) GB0317009D0 (fr)
HU (4) HUE059970T2 (fr)
MX (1) MXPA05012606A (fr)
NO (1) NO333603B1 (fr)
NZ (1) NZ541974A (fr)
PL (4) PL3904365T3 (fr)
PT (4) PT1646639T (fr)
SI (2) SI3040340T1 (fr)
TR (1) TR201901246T4 (fr)
WO (1) WO2005012327A2 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180346504A1 (en) * 2017-05-01 2018-12-06 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US10988498B2 (en) 2009-09-21 2021-04-27 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
US11007208B2 (en) 2015-09-16 2021-05-18 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
US11260070B2 (en) 2017-03-14 2022-03-01 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
US11266681B2 (en) 2017-07-11 2022-03-08 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US11266666B2 (en) 2014-10-29 2022-03-08 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
US11377467B2 (en) 2015-12-23 2022-07-05 NuCana plc Crystalline form of gemcitabine
US11492353B2 (en) 2010-07-22 2022-11-08 Gilead Sciences, Inc. Methods and compounds for treating Paramyxoviridae virus infections
US11491169B2 (en) 2020-05-29 2022-11-08 Gilead Sciences, Inc. Remdesivir treatment methods
US11560400B2 (en) 2017-12-05 2023-01-24 NuCana plc Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
US11780844B2 (en) 2022-03-02 2023-10-10 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11814406B2 (en) 2020-08-27 2023-11-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462605B2 (en) 1998-01-23 2008-12-09 Celmed Oncology (Usa), Inc. Phosphoramidate compounds and methods of use
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
PL359169A1 (en) 2000-05-26 2004-08-23 Idenix (Cayman) Limited Methods and compositions for treating flaviviruses and pestiviruses
CN101172993A (zh) 2002-06-28 2008-05-07 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
AU2003248748A1 (en) 2002-06-28 2004-01-19 Idenix (Cayman) Limited 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections
BR0316363A (pt) 2002-11-15 2005-10-04 Idenix Cayman Ltd Nucleosìdeos 2'-ramificado e mutação de flaviviridae
RU2005121904A (ru) 2002-12-12 2006-01-20 Айденикс (Кайман) Лимитед (Ky) Способ получения 2`-разветвленных нуклеозидов
MXPA05012788A (es) 2003-05-30 2006-02-22 Pharmasset Inc Analogos de nucleosidos fluorados modificados.
CN101023094B (zh) * 2004-07-21 2011-05-18 法莫赛特股份有限公司 烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
KR101177590B1 (ko) 2004-09-14 2012-08-27 파마셋 인코포레이티드 2'-플루오로-2'-알킬 치환되거나 또는 다른 선택적으로치환된 리보퓨라노실 피리미딘 및 퓨린 및 그 유도체의제조
EP1827460A4 (fr) 2004-12-09 2012-03-14 Univ Minnesota Nucleosides presentant une activite antivirale et anticancereuse
GB0505781D0 (en) * 2005-03-21 2005-04-27 Univ Cardiff Chemical compounds
DE102006037786A1 (de) 2006-08-11 2008-03-20 Resprotect Gmbh Nukleoside, diese enthaltendes Arzneimittel und deren Verwendung
ATE551061T1 (de) * 2006-11-13 2012-04-15 Santaris Pharma As Lna-nukleosid-phosphoramidate
GB0623493D0 (en) 2006-11-24 2007-01-03 Univ Cardiff Chemical compounds
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
AU2014233579B2 (en) * 2007-03-30 2016-06-23 Gilead Sciences, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
FR2922551B1 (fr) * 2007-10-17 2009-12-25 Univ Claude Bernard Lyon Prodrogues phosphoesters de la gemcitabine comme agents anticancereux
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
TW201026715A (en) 2008-12-23 2010-07-16 Pharmasset Inc Nucleoside phosphoramidates
EP2376514A2 (fr) 2008-12-23 2011-10-19 Pharmasset, Inc. Analogues de nucléoside
AU2009329872B2 (en) * 2008-12-23 2016-07-07 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US9676797B2 (en) 2015-09-02 2017-06-13 Abbvie Inc. Anti-viral compounds
WO2011123645A2 (fr) 2010-03-31 2011-10-06 Pharmasset, Inc. Phosphoramidates de nucléosides
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
CN103209987B (zh) 2010-09-22 2017-06-06 艾丽奥斯生物制药有限公司 取代的核苷酸类似物
GB201016855D0 (en) * 2010-10-06 2010-11-17 Nucana Biomed Ltd Chemical compounds
EP3042910B1 (fr) 2010-11-30 2019-01-09 Gilead Pharmasset LLC 2'-spiro-nucléosides pour le traitement de l'hépatite c
US9095599B2 (en) 2011-01-03 2015-08-04 Nanjing Molecular Research, Inc. O-(substituted benzyl) phosphoramidate compounds and therapeutic use
US9156874B2 (en) 2011-01-03 2015-10-13 Nanjing Molecular Research, Inc. Double-liver-targeting phosphoramidate and phosphonoamidate prodrugs
ES2686219T3 (es) * 2011-03-01 2018-10-16 NuCana plc Compuestos químicos
EP2691409B1 (fr) 2011-03-31 2018-02-21 Idenix Pharmaceuticals LLC. Composés et compositions pharmaceutiques pour le traitement d'infections virales
TW201329096A (zh) 2011-09-12 2013-07-16 Idenix Pharmaceuticals Inc 經取代羰氧基甲基磷酸醯胺化合物及用於治療病毒感染之藥學組成物
BR112014006324B8 (pt) 2011-09-16 2019-02-12 Gilead Pharmassett Llc composição e seu uso para o tratamento de hcv
EP2768838A1 (fr) 2011-10-14 2014-08-27 IDENIX Pharmaceuticals, Inc. Phosphates 3',5'-cycliques substitués de composés nucléotidiques purines et compositions pharmaceutiques pour le traitement d'infections virales
CN103826627B (zh) 2011-10-21 2016-02-24 艾伯维公司 包含至少两种直接抗病毒剂和利巴韦林的组合物在制备治疗hcv的药物中的用途
ES2527544T1 (es) 2011-10-21 2015-01-26 Abbvie Inc. Tratamiento mono (PSI-7977) o de combinación con AAD para su uso en el tratamiento del VHC
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SG11201403086YA (en) 2011-12-20 2014-07-30 Hoffmann La Roche 4'-azido, 3'-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
EP2794629B1 (fr) 2011-12-20 2017-05-24 Riboscience LLC Dérivés de nucléoside substitué 2',4'-difluoro-2'-méthyle en tant qu'inhibiteurs de la réplication de l'arn du vhc (virus de l'hépatite c)
EP2794630A4 (fr) 2011-12-22 2015-04-01 Alios Biopharma Inc Analogues de nucléotide phosphorothioate substitués
US8916538B2 (en) 2012-03-21 2014-12-23 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
EP2827876A4 (fr) 2012-03-22 2015-10-28 Alios Biopharma Inc Combinaisons pharmaceutiques comprenant un analogue thionucléotidique
MX352423B (es) 2012-03-28 2017-11-24 Fujifilm Corp Sal de 1-(2-desoxi-2-fluoro-4-tio-beta-d-arabinofuranosil) citosina.
EP2852604B1 (fr) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC Promédicaments de 3',5'-phosphoramidate cyclique pour traiter une infection par le virus de l'hépatite c
SG11201407674TA (en) 2012-05-22 2014-12-30 Idenix Pharmaceuticals Inc D-amino acid compounds for liver disease
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
EP2861611B1 (fr) 2012-05-25 2016-07-13 Janssen Sciences Ireland UC Nucléosides dýuracyle spirooxetane
WO2013187978A1 (fr) * 2012-06-16 2013-12-19 Nanjing Molecular Research, Inc. Promédicaments de phosphoramidate et phosphonoamidate à double ciblage hépatique
EP3184112B1 (fr) 2012-08-13 2020-12-23 FUJIFILM Corporation INTERMÉDIAIRE DE SYNTHÈSE DE CYTOSINE 1- (2-DEOXY-2-FLUORO-4-THIO-ß-D-ARABINOFURANOSYL)
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
EP2900682A1 (fr) 2012-09-27 2015-08-05 IDENIX Pharmaceuticals, Inc. Esters et malonates de promédicaments à base de s-acyl-2-thioéthyle (sate)
SG11201502750UA (en) 2012-10-08 2015-06-29 Idenix Pharmaceuticals Inc 2'-chloro nucleoside analogs for hcv infection
US10723754B2 (en) 2012-10-22 2020-07-28 Idenix Pharmaceuticals Llc 2′,4′-bridged nucleosides for HCV infection
PT3150616T (pt) * 2012-11-16 2017-06-09 Univ College Cardiff Consultants Ltd Mistura de rp/sp gencitabina-[fenil-(benziloxi-l-alaninil)]-fosfato
WO2014099941A1 (fr) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro-nucléosides pour le traitement du vhc
MY172166A (en) 2013-01-31 2019-11-15 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US10034893B2 (en) 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
WO2014137930A1 (fr) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Nucléosides de thiophosphate pour le traitement du vhc
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014160484A1 (fr) 2013-03-13 2014-10-02 Idenix Pharmaceuticals, Inc. Pronucléotides de phosphoramidate d'acide aminé de 2'-cyano, azido et amino nucléosides pour le traitement du virus de l'hépatite c (vhc)
EP2981542B1 (fr) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoronucléosides pour le traitement du vhc
AU2014250762A1 (en) 2013-04-12 2015-10-29 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of HCV
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
WO2014186637A1 (fr) 2013-05-16 2014-11-20 Riboscience Llc Dérivés de nucléosides 4'-fluoro-2'-méthyle substitués
CA2912684A1 (fr) 2013-05-16 2014-12-04 Riboscience Llc Derives nucleosidiques 4'-azido, 3'desoxy-3'-fluoro substitues
EP3004130B1 (fr) 2013-06-05 2019-08-07 Idenix Pharmaceuticals LLC. 1',4'-thio nucléosides pour le traitement du virus de l'hépatite c (vhc)
EP3027636B1 (fr) 2013-08-01 2022-01-05 Idenix Pharmaceuticals LLC Phosphoramidate de d-acides aminés pronucleotidiques dérivés de pyrimidine halogenée pour des maladies du foie
WO2015030853A1 (fr) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Préparation combinée de deux composés antiviraux
EP3057976A1 (fr) * 2013-10-17 2016-08-24 Medivir Ab Inhibiteurs de la polymérase du vhc
EP3074411A2 (fr) 2013-11-27 2016-10-05 Idenix Pharmaceuticals LLC Nucléotides pour le traitement du cancer du foie
WO2015125781A1 (fr) 2014-02-18 2015-08-27 富士フイルム株式会社 Composé de sucre type squelette de thiolane et procédé de fabrication de celui-ci
JP6204223B2 (ja) 2014-02-19 2017-09-27 富士フイルム株式会社 チオピラノース化合物等の製造方法
CN103804446A (zh) * 2014-02-27 2014-05-21 苏州东南药业股份有限公司 一种3,5-二苯甲酰基-2-去氧-2-氟-2甲基-D-核糖-γ-内酯的制备方法
WO2015161137A1 (fr) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. Nucléosides méthyle ou alcynyle substitués en position 3 pour le traitement du virus de l'hépatite c
AU2015278899B2 (en) 2014-06-25 2019-07-18 NuCana plc Gemcitabine prodrugs
HUE036011T2 (hu) 2014-06-25 2018-06-28 NuCana plc Készítmény, mely tartalmaz egy gemcitabin-pro-gyógyszert
US9834577B2 (en) 2014-07-22 2017-12-05 Laurus Labs Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
PT3572410T (pt) 2014-08-25 2022-09-15 Medivir Ab Análogos dioxolano de uridina para o tratamento de cancro
WO2016033164A1 (fr) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Dérivés de nucléosides et de nucléotides
GB201417644D0 (en) 2014-10-06 2014-11-19 Nucana Biomed Ltd Method of separating phosphate diastereoisomers
TWI678373B (zh) * 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
EP3212658A4 (fr) * 2014-10-31 2018-07-25 Cocrystal Pharma, Inc. Analogues de 2',2'-dihalo-nucléosides utilisables en vue du traitement d'infections par des virus de la famille des flaviviridae et du cancer
WO2016073756A1 (fr) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Dérivés de nucléosides/nucléotides deutérés
ME03462B (fr) 2014-11-28 2020-01-20 NuCana plc Nouveaux dérivés de 3'-désoxyadénosine présentant un fragment ester de phosphoramidate et d'acide aminé 2' et/ou 5' comme composés anticancéreux
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
BR112017012859A2 (pt) 2014-12-15 2017-12-26 Univ Emory fosforamidatos para o tratamento do vírus da hepatite b
WO2016134058A1 (fr) 2015-02-18 2016-08-25 Abbvie Inc. Combinaisons utiles pour traiter le virus de l'hépatite c
RU2764767C2 (ru) 2015-03-06 2022-01-21 Атеа Фармасьютикалс, Инк. β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-С-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ
AU2016240117C1 (en) * 2015-04-03 2020-11-26 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
LT3197456T (lt) 2015-05-14 2018-07-10 NuCana plc Vėžio gydymas
TWI687431B (zh) * 2015-06-22 2020-03-11 瑞典商米迪維艾克提伯拉公司 治療癌症之前藥
CN106543252A (zh) * 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 核苷氨基磷酸酯类前药的制备方法及其中间体
CN112156102B (zh) * 2015-09-16 2023-10-03 济南高合医疗科技有限公司 一种nuc-1031单一异构体的晶型及其制备方法
CN106543220A (zh) 2015-09-16 2017-03-29 博瑞生物医药（苏州）股份有限公司 氨基磷酸酯化合物及其制备方法和晶体
WO2017060661A1 (fr) * 2015-10-05 2017-04-13 Nucana Biomed Limited Polythérapie
WO2017087517A1 (fr) * 2015-11-16 2017-05-26 Demeter Therapeutics, Llc Promédicaments d'acides nucléiques
CN115746073A (zh) * 2015-12-11 2023-03-07 努卡那有限公司 磷酸酯衍生物和吉西他滨前药nuc-1031的非对映选择性合成
ME03677B (fr) 2015-12-23 2020-10-20 NuCana plc Polythérapie
CA3008769A1 (fr) 2015-12-23 2017-06-29 NuCana plc Therapie combinee comprenant nuc-1031 et un cisplatine
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
GB201609600D0 (en) * 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
CA3029315A1 (fr) 2016-06-24 2017-12-28 Emory University Phosphoramidates pour le traitement du virus de l'hepatite b
WO2018013937A1 (fr) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Nucléotides de purine beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substitué-4'-fluoro-n6-substitué-6-amino-2-substitué pour le traitement de l'infection par le virus de l'hépatite c
IL265044B2 (en) 2016-08-31 2025-02-01 Fujifilm Corp An antitumor preparation containing the substances nab-paclitaxel and 1-(2-deoxy-2-fluoro-4-thio-D-beta-arabinofurnosyl)cytosine, a kit containing these substances and their uses
CN109689672B (zh) 2016-09-07 2023-05-30 阿堤亚制药公司 用于rna病毒治疗的2’-取代的-n6-取代的嘌呤核苷酸
GB201709471D0 (en) 2017-06-14 2017-07-26 Nucana Biomed Ltd Diastereoselective synthesis of hosphate derivatives
CN109134568B (zh) * 2017-06-15 2022-11-22 北京美倍他药物研究有限公司 核苷磷酸酯/酰胺衍生物及其医药用途
WO2019042226A1 (fr) * 2017-09-01 2019-03-07 四川科伦博泰生物医药股份有限公司 Composition pharmaceutique pour le traitement ou la prévention de tumeurs, méthode et utilisation de celle-ci
GB201715011D0 (en) 2017-09-18 2017-11-01 Nucana Biomed Ltd Floxuridine synthesis
AU2018335411B2 (en) 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
WO2019146130A1 (fr) 2018-01-29 2019-08-01 富士フイルム株式会社 Agent antitumoral contre le cancer biliaire et méthode de traitement du cancer biliaire
BR112020015747A2 (pt) * 2018-02-02 2020-12-08 Maverix Oncology, Inc. Conjugados de fármaco de moléculas pequenas de derivados de gemcitabina
JP2021512953A (ja) 2018-02-02 2021-05-20 メイベリックス オンコロジー インコーポレイテッド ゲムシタビンモノホスフェートの小分子薬物コンジュゲート
JP6810763B2 (ja) * 2019-03-06 2021-01-06 ニューカナ パブリック リミテッド カンパニー がん治療
GB201904544D0 (en) 2019-04-01 2019-05-15 NuCana plc Anticancer compounds
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
WO2021173713A1 (fr) 2020-02-27 2021-09-02 Atea Pharmaceuticals, Inc. Composés hautement actifs contre la covid-19
WO2022031150A1 (fr) * 2020-08-07 2022-02-10 주식회사 피노바이오 Conjugué comprenant un agent anticancéreux à base de désoxycytidine et un lieur contenant un éther de silyle

Citations (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US2945038A (en) 1956-09-26 1960-07-12 Hoffmann La Roche 5-fluorocytosine and preparation thereof
US3201387A (en) 1963-09-18 1965-08-17 Heidelberger Charles 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US5814639A (en) 1990-02-01 1998-09-29 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
WO1999037753A1 (fr) 1998-01-23 1999-07-29 Newbiotics, Inc. Agents therapeutiques obtenus par catalyse enzymatique
WO1999049873A1 (fr) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides presentant une activite antivirale et anticancereuse
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US6180639B1 (en) 1990-05-02 2001-01-30 Biochem Pharma Inc. 1,3-oxathiolane nucleoside analogues
WO2001007454A1 (fr) 1999-07-22 2001-02-01 Newbiotics, Inc. Activation therapeutique catalysee par des enzymes
WO2003000713A1 (fr) 2001-06-21 2003-01-03 Glaxo Group Limited Composes nucleosides pour vhc
US20030109697A1 (en) * 1998-01-23 2003-06-12 Shepard H. Michael Novel phosphoramidate compounds and methods of use
WO2003053989A1 (fr) * 2001-12-13 2003-07-03 Mrc Technology Limited Derives nucleosides contenant un phosphate masque, et leur utilisation comme agents antiviraux
WO2003068164A2 (fr) 2002-02-14 2003-08-21 Pharmasset Ltd. Schema posologique pour le traitement par gemcitabine du virus de l'hepatite c
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
WO2004041203A2 (fr) 2002-11-04 2004-05-21 Xenoport, Inc. Promedicaments de gemcitabine, leurs compositions pharmaceutiques et leurs utilisations
US20040167096A1 (en) * 2003-02-19 2004-08-26 Yung-Chi Cheng Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections
US20170226147A1 (en) * 2014-10-06 2017-08-10 Nucana Biomed Limited Methods of separating gemcitabine-phosphate diastereoisomers
US9834577B2 (en) 2014-07-22 2017-12-05 Laurus Labs Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
US10005810B2 (en) 2012-11-16 2018-06-26 University College Cardiff Consultants Limited Process for preparing nucleoside prodrugs
US20180271889A1 (en) 2015-10-05 2018-09-27 NuCana plc Combination therapy for cancer
US20180289733A1 (en) 2015-05-14 2018-10-11 NuCana plc Cancer treatments based on gemcitabine prodrugs
US10117888B2 (en) 2014-06-25 2018-11-06 NuCana plc Formulation comprising a gemcitabine-prodrug
US20180362571A1 (en) 2015-12-11 2018-12-20 NuCana plc Diastereoselective synthesis of phosphate derivatives
US20180369266A1 (en) 2015-12-23 2018-12-27 NuCana plc Formulations of phosphoramidate derivatives of nucleoside drugs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2538397A1 (fr) 1982-12-24 1984-06-29 Charbonnages Ste Chimique Procede continu de fabrication d'homopolymeres ou de copolymeres de l'ethylene
GB9505025D0 (en) 1995-03-13 1995-05-03 Medical Res Council Chemical compounds
EP1251836A2 (fr) 1999-12-23 2002-10-30 NewBiotics, Inc. Utilisation de bvdu pour inhiber la croissance de cellules hyperproliferantes
US20020147175A1 (en) 2000-11-16 2002-10-10 Shepard H. Michael Synergistic ECTA compositions
WO2004002999A2 (fr) 2002-06-28 2004-01-08 Idenix (Cayman) Limited Promedicaments a nucleosides 2' et 3' destines a traiter les infections aux flavivirus
MXPA05012788A (es) 2003-05-30 2006-02-22 Pharmasset Inc Analogos de nucleosidos fluorados modificados.

Patent Citations (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US2945038A (en) 1956-09-26 1960-07-12 Hoffmann La Roche 5-fluorocytosine and preparation thereof
US3201387A (en) 1963-09-18 1965-08-17 Heidelberger Charles 5-trifluoromethyluracil, derivatives thereof, and processes for preparing the same
US4357324A (en) 1981-02-24 1982-11-02 The United States Of America As Represented By The Department Of Health And Human Services Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine
US6069252A (en) 1990-02-01 2000-05-30 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers
US5914331A (en) 1990-02-01 1999-06-22 Emory University Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
US6703396B1 (en) 1990-02-01 2004-03-09 Emory University Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
US5814639A (en) 1990-02-01 1998-09-29 Emory University Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
US6180639B1 (en) 1990-05-02 2001-01-30 Biochem Pharma Inc. 1,3-oxathiolane nucleoside analogues
WO1999037753A1 (fr) 1998-01-23 1999-07-29 Newbiotics, Inc. Agents therapeutiques obtenus par catalyse enzymatique
JP2001220397A (ja) 1998-01-23 2001-08-14 Newbiotics Inc 酵素に触媒される治療剤
JP2002500880A (ja) 1998-01-23 2002-01-15 ニューバイオティックス インコーポレイテッド 酵素に触媒される治療剤
US6339151B1 (en) * 1998-01-23 2002-01-15 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
US20030109697A1 (en) * 1998-01-23 2003-06-12 Shepard H. Michael Novel phosphoramidate compounds and methods of use
WO1999049873A1 (fr) 1998-03-27 1999-10-07 Regents Of The University Of Minnesota Nucleosides presentant une activite antivirale et anticancereuse
WO2001007454A1 (fr) 1999-07-22 2001-02-01 Newbiotics, Inc. Activation therapeutique catalysee par des enzymes
WO2003000713A1 (fr) 2001-06-21 2003-01-03 Glaxo Group Limited Composes nucleosides pour vhc
WO2003053989A1 (fr) * 2001-12-13 2003-07-03 Mrc Technology Limited Derives nucleosides contenant un phosphate masque, et leur utilisation comme agents antiviraux
WO2003068164A2 (fr) 2002-02-14 2003-08-21 Pharmasset Ltd. Schema posologique pour le traitement par gemcitabine du virus de l'hepatite c
WO2004041203A2 (fr) 2002-11-04 2004-05-21 Xenoport, Inc. Promedicaments de gemcitabine, leurs compositions pharmaceutiques et leurs utilisations
US20040167096A1 (en) * 2003-02-19 2004-08-26 Yung-Chi Cheng Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections
US10005810B2 (en) 2012-11-16 2018-06-26 University College Cardiff Consultants Limited Process for preparing nucleoside prodrugs
US20180273575A1 (en) 2012-11-16 2018-09-27 NuCana plc Process for preparing nucleoside prodrugs
US10117888B2 (en) 2014-06-25 2018-11-06 NuCana plc Formulation comprising a gemcitabine-prodrug
US20190022118A1 (en) 2014-06-25 2019-01-24 NuCana plc Formulation comprising a gemcitabine-prodrug
US9834577B2 (en) 2014-07-22 2017-12-05 Laurus Labs Limited Process for the preparation of gemcitabine-[phenyl(benzoxy-L-alaninyl)] phosphate
US20170226147A1 (en) * 2014-10-06 2017-08-10 Nucana Biomed Limited Methods of separating gemcitabine-phosphate diastereoisomers
US20180289733A1 (en) 2015-05-14 2018-10-11 NuCana plc Cancer treatments based on gemcitabine prodrugs
US20180271889A1 (en) 2015-10-05 2018-09-27 NuCana plc Combination therapy for cancer
US20180362571A1 (en) 2015-12-11 2018-12-20 NuCana plc Diastereoselective synthesis of phosphate derivatives
US20180369266A1 (en) 2015-12-23 2018-12-27 NuCana plc Formulations of phosphoramidate derivatives of nucleoside drugs

Non-Patent Citations (33)

* Cited by examiner, † Cited by third party
Title
Abraham et al., "Synthesis and Biological Activity of Aromatic Amino Acid Phosphoramidates of 5-Fluoro-2'-deoxyuridine and 1-beta-Arabinofuranosylcytosine: Evidence of Phosphoramidate Activity", J. Med. Chem. 39:4569-4575 (1996).
Bundgard, H. in "Design of Prodrugs" (Bungaard, H., ed.) (1985) (Elsevier Science Publishers, Biomedical Division: Amsterdam) pp. 1-92. *
David B. Lackey et al., "Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase", Biochemical Pharmacology, 61 (2001), pp. 179-189.
Edward J. McIntee, et al., "Amino Acid Phosphoramidate Nucleosides: Potential ADEPT/GDEPT Substrates", Bioorganic & Medicinal Chemistry Letters, 11 (2001), pp. 2803-2805.
Galmarini, C. M., et al. Leukemia (2001). 15; pp. 875-890. *
Gromova et al., "Optical Rotary Dispersion and Circular Dichroism of Mono- and Oligonucleotide-Amino Acids (Amidates)", Biochim Biophys Acta 240:1-11 (1971).
Harris et al., "Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromoviny1)-2'-deoxyuridine", Antiviral Chemistry and Chemotherapy, vol. 12 (2001), pp. 293-300.
Juodka et al., "Oligonucleotides and nucleotide-peptide. XXXIV. Synthesis and some properties of complex nucleotidyl (oligonucleotidyl)-(P-N)-aminoacids (peptides) and their ethyl esters"; J Carbohydrates Nucleosides Nucleotides 6(4):333-357 (1979).
Juodka et al., "Oligonucleotides and Nucleotide-Peptides. XXXV. Some Properties of Nucleotidyl-(5'→N)-Amino Acid Esters Differing in Amino Acid and Nucleotide Components)", J Carbohydrates Nucleosides Nucleotides 8 (1): 19-39 (1981).
Juodka et al., "Oligonucleotides and nucleotide-peptides. XXXVII. On the Mechanism of Hydrolysis of Uridyly1-(5'→N)-amino acids. Intramolecular catalysis by the alpha-carboxyl group of amino acids"; J Carbohydrates Nucleosides Nucleotides 8(6):519-535 (1981).
Juodka et al., "Oligonucleotides and Nucleotide-Peptides. XXXV. Some Properties of Nucleotidyl—(5'→N)-Amino Acid Esters Differing in Amino Acid and Nucleotide Components)", J Carbohydrates Nucleosides Nucleotides 8 (1): 19-39 (1981).
Lehsten et al., "An improved procedure for the synthesis of nucleoside amidates"; Organic Process Research & Development 6:819-822 (2002).
Liorancaite et al., "Synthesis and Some Properties of Oligonucleotidyl-(Pm->N)-Serines", Nucleic Acids Symposium Series 9:215-18 (1981).
Lisa J. Whalen, et al., "Synthesis and Evaluation of Phosphoramidate Amino Acid-Based Inhibitors of Sialyltransferases", Bioorganic & Medicinal Chemistry Letters, 13 (2003), pp. 301-304.
McGuigan et al. Antiviral Chem. Chemotherapy (2000) 11: 111-116. *
McGuigan et al. Antiviral Chemistry & Chemotherapy 1993; 4:97-101.
McGuigan et al. Antiviral Research 1991; 15:255-263.
McGuigan et al., "Synthesis and Evaluation of some masked phosphate esters of the anti-herpesvirus drug 882C (Netivudine) as potential antiviral agents", Antiviral Chemistry & Chemotherapy 9:233-243 (1998).
Negishi et al., "N4-Aminocytidine, a Nucleoside Analog that has an Exceptionally High Mutagenic Activity", Nucleic Acids Research 11(15):5223-5233 (1993).
Parker et al. Mol. Pharmacol. 1999; 55:515-520.
Patani et al. Chem. Rev. (1996) 96: 3147-3176. *
Ramirez, M et al. Prostaglandins, Leukotrienes and Essential Fatty Acids 1991; 43: 49-54.
Remy et al., "Studies on fluorinated pyrimidines. XIV. The synthesis of derivatives of 5-fluoro-2'-deoxyuridine-5'-phosphate and related compounds"; J Org Chem 27:2491-2500 (1962).
Sa Harris, et al., "Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromovinyl)-2′-deoxyuridine", Antiviral Chemistry and Chemotherapy, vol. 12 (2001), pp. 293-300.
Search Report issued by the European Patent Office in corresponding Application No. EP 15154759.3, dated Jun. 20, 2017.
Siddiqui et al., "Design and Synthesis of Liphophilic Phosphoramidate d4T-MP Prodrugs Expressing High Potency Against HIV in Cell Culture: Structure Determinants for in Vitro Activity and QSAR", J Med Chem 42 (1999), pp. 4122-4128.
Slusarczyk, "Application of ProTide Technology to Gemcitabine: A Successful Approach to Overcome the Key Cancer Resistance Mechanisms Leads to a New Agent (NUC-1031) in Clinical Development," J Med Chem, 57:1531-1542 (2014).
Stryer, L., "DNA and RNA: Molecules of Heredity", Biochemistry, Fourth Ed., Ch. 4. pp. 75, 76, 80-83 (1995).
Stryer, L., "Flow of Genetic Information". Biochemistry, Fourth Ed., Ch. 5, pp. 95-97 (1995).
Torres-Lopez, MI. Et al. Gut 1996; 38: 260-264.
Wagner, et al. Bioorganic & Medicinal Chemistry Letters 1995; 5 (16):1819-1824.
Wattig, B. et al. Acta Histochem Suppl. 1992; 42:333-339 (Abstract only).
Zhou et al., "Simultaneous Formation of Peptides and Nucleotides from N-Phosphothreonine", Origins of Life and Evolution of the Biosphere 26:547-560 (1996).

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10988498B2 (en) 2009-09-21 2021-04-27 Gilead Sciences, Inc. Processes and intermediates for the preparation of 1′-substituted carba-nucleoside analogs
US11492353B2 (en) 2010-07-22 2022-11-08 Gilead Sciences, Inc. Methods and compounds for treating Paramyxoviridae virus infections
US11344565B2 (en) 2014-10-29 2022-05-31 Gilead Sciences, Inc. Methods for the preparation of ribosides
US11266666B2 (en) 2014-10-29 2022-03-08 Gilead Sciences, Inc. Methods for treating Filoviridae virus infections
US11007208B2 (en) 2015-09-16 2021-05-18 Gilead Sciences, Inc. Methods for treating arenaviridae and coronaviridae virus infections
US11382926B2 (en) 2015-09-16 2022-07-12 Gilead Sciences, Inc. Methods for treating Arenaviridae and Coronaviridae virus infections
US11377467B2 (en) 2015-12-23 2022-07-05 NuCana plc Crystalline form of gemcitabine
US11260070B2 (en) 2017-03-14 2022-03-01 Gilead Sciences, Inc. Methods of treating feline coronavirus infections
US10836787B2 (en) * 2017-05-01 2020-11-17 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
US12030906B2 (en) 2017-05-01 2024-07-09 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US11597742B2 (en) 2017-05-01 2023-03-07 Gilead Sciences, Inc. Crystalline forms of (S)-2-ethylbutyl 2-(((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US20180346504A1 (en) * 2017-05-01 2018-12-06 Gilead Sciences, Inc. Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5- (4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy) (phenoxy) phosphoryl)amino)propanoate
US11266681B2 (en) 2017-07-11 2022-03-08 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US11975017B2 (en) 2017-07-11 2024-05-07 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
US11560400B2 (en) 2017-12-05 2023-01-24 NuCana plc Salts of diphosphate phosphoramidate of nucleosides as anticancer compounds
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
US11613553B2 (en) 2020-03-12 2023-03-28 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
US12012431B2 (en) 2020-03-12 2024-06-18 Gilead Sciences, Inc. Methods of preparing 1′-cyano nucleosides
US11701372B2 (en) 2020-04-06 2023-07-18 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs
US11975012B2 (en) 2020-05-29 2024-05-07 Gilead Sciences, Inc. Remdesivir treatment methods
US11491169B2 (en) 2020-05-29 2022-11-08 Gilead Sciences, Inc. Remdesivir treatment methods
US11903953B2 (en) 2020-05-29 2024-02-20 Gilead Sciences, Inc. Remdesivir treatment methods
US11939347B2 (en) 2020-06-24 2024-03-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and uses thereof
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11814406B2 (en) 2020-08-27 2023-11-14 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US12297226B2 (en) 2020-08-27 2025-05-13 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11780844B2 (en) 2022-03-02 2023-10-10 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US11851438B2 (en) 2022-03-02 2023-12-26 Gilead Sciences, Inc. 1′-cyano nucleoside analogs and methods for treatment of viral infections
US11845755B2 (en) 2022-03-02 2023-12-19 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
US12180217B2 (en) 2022-03-02 2024-12-31 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections

Also Published As

Publication number Publication date
TR201901246T4 (tr) 2019-02-21
FR23C1014I1 (fr) 2023-05-05
NO333603B1 (no) 2013-07-22
CA2518115A1 (fr) 2005-02-10
US20060142238A1 (en) 2006-06-29
DK2955190T3 (en) 2018-05-22
HUE030374T2 (en) 2017-05-29
PL2955190T3 (pl) 2018-09-28
MXPA05012606A (es) 2006-02-08
PT3904365T (pt) 2022-10-13
DK1646639T3 (en) 2016-09-12
EP3904365B1 (fr) 2022-09-07
NO20053993L (no) 2005-11-02
CY1121218T1 (el) 2020-05-29
EP2955190B1 (fr) 2018-03-28
ES2589738T3 (es) 2016-11-16
HUS2300012I1 (hu) 2023-03-28
ES2667698T3 (es) 2018-05-14
EP1646639B8 (fr) 2016-12-21
PL3904365T3 (pl) 2022-11-07
EP3486251A1 (fr) 2019-05-22
PT1646639T (pt) 2016-09-05
FIC20230013I1 (fi) 2023-03-01
EP3040340A1 (fr) 2016-07-06
PL1646639T3 (pl) 2016-12-30
DK3040340T3 (en) 2019-02-25
CY1125603T1 (el) 2023-06-09
NO20053993D0 (no) 2005-08-26
JP2006528162A (ja) 2006-12-14
PT3040340T (pt) 2019-02-06
CY2023008I2 (el) 2024-02-16
ES2928202T3 (es) 2022-11-16
EP1646639A2 (fr) 2006-04-19
CY1120202T1 (el) 2018-12-12
ES2708570T3 (es) 2019-04-10
FR23C1014I2 (fr) 2024-02-09
WO2005012327A3 (fr) 2005-04-21
EP3040340B1 (fr) 2018-11-14
HUE042282T2 (hu) 2019-06-28
PT2955190T (pt) 2018-05-07
CY2023008I1 (el) 2024-02-16
US7951787B2 (en) 2011-05-31
HUE059970T2 (hu) 2023-01-28
AU2004261455A1 (en) 2005-02-10
PL3040340T3 (pl) 2019-05-31
JP4923216B2 (ja) 2012-04-25
GB0317009D0 (en) 2003-08-27
EP2955190A2 (fr) 2015-12-16
WO2005012327A2 (fr) 2005-02-10
EP2955190A3 (fr) 2016-03-16
EP3904365A1 (fr) 2021-11-03
AU2004261455B2 (en) 2010-12-23
CY1117960T1 (el) 2017-05-17
EP1646639B1 (fr) 2016-08-17
CA2518115C (fr) 2012-03-20
DK3904365T3 (da) 2022-10-17
SI3040340T1 (sl) 2019-03-29
NZ541974A (en) 2009-03-31
SI2955190T1 (en) 2018-08-31

Similar Documents

Publication Publication Date Title
USRE47589E1 (en) Phosphoramidate compounds and methods of use
AU2012223012C1 (en) Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer
US9321798B2 (en) Phosphoramidite derivatives of gemcitabine for use in the treatment of cancer
AU610344B2 (en) 2'-deoxy-5-fluorouridine derivatives
PT707591E (pt) Esteres de acido metilfosfonico, processo para a sua preparacao e sua utilizacao
US11414451B2 (en) Floxuridine synthesis
CZ295706B6 (cs) Derivát 5´-deoxycytidinu, způsob jeho výroby a použití a farmaceutická kompozice a kit s jeho obsahem
Daumar et al. Design, synthesis and in vitro drug release investigation of new potential 5-FU prodrugs
KR20070103012A (ko) 신규 피리미딘 뉴클레오시드화합물 또는 그의 염
JPWO2008010571A1 (ja) ２’−シアノピリミジンヌクレオシド化合物
GB2104060A (en) Fluorinated hexene diamine derivatives

Legal Events

Date Code Title Description
AS Assignment

Owner name: NUCANA PLC, UNITED KINGDOM

Free format text: CHANGE OF NAME;ASSIGNOR:NUCANA BIOMED LIMITED;REEL/FRAME:048621/0306

Effective date: 20170829

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载